Association between anticoagulant therapy,exacerbations and mortality in a Danish cohort of patients with Chronic Obstructive Pulmonary Disease

Abstract

Objectives:

Pulmonary Embolism has been frequently reported in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD). The study aimed to determine whether COPD patients who receive anticoagulant (AC) therapy have a reduced risk of hospitalization due to AE-COPD and death.

Methods:

This nationwide population-based study was based on data from the Danish Register of COPD (DrCOPD), which contains complete data on COPD outpatients between 1st January 2010 and 31st December 2018. National registers were used to obtain information regarding comorbidities and vital status. Propensity-score matching and Cox proportional hazards models were used to assess AE-COPD and death after one year.

Results:

The study cohort consisted of 58,067 patients with COPD. Of these, 5194 patients were on AC therapy. The population was matched 1:1 based on clinical confounders and AC therapy, resulting in two groups of 5180 patients. We found no association between AC therapy and AE-COPD or all-cause mortality in the propensity-score matched population (HR 1.03, 95% CI 0.96-1.10, p = 0.37). These findings were confirmed in a competing risk analysis. In the sensitivity analysis, we performed an adjusted analysis of the complete cohort and found a slightly increased risk of AE-COPD or death in patients treated with AC therapy. This study found a low incidence of pulmonary embolisms and deep venous thrombosis in both groups.

Conclusions:

AC therapy was not associated with the risk of hospitalization due to AE-COPD or all-cause mortality.

Keywords

Chronic obstructive pulmonary disease COPD anticoagulant therapy venous tromboembolism pulmonary embolism

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in the world.¹ Patients with COPD can experience recurrent acute exacerbations of COPD (AE-COPD), which are defined as clinical symptoms e.g. dyspnoea, increased sputum, and coughing combined with positive biomarkers e.g. increased C-reactive protein, eosinophilia, or neutrophilia.² The causes of AE-COPD are heterogeneous³ and the condition is associated with impaired health status and a worsened prognosis.^4,5 In addition to microbiological agents, pulmonary embolisms (PE) can be an important factor in the etiology of AE-COPD. According to a systematic review and meta-analysis of 7 studies and a total of 880 patients, PE was found in 16.1% of unexplained AE-COPD (95% confidence interval (CI), 8.3%−25.8%; p < .0001). The prevalence of deep venous thrombosis (DVT) in undescribed AE-COPD was 10.5% (95% CI, 4.3%–19.0%; p < .0001).⁶ A recent study found a lower, but still substantial risk of 5.9% for PE during AE-COPD admission.⁷

In general, patients with COPD and especially AE-COPD have been demonstrated to have a higher platelet activation.⁸ A community study evaluating data from 14,654 participants between 1987 and 1989, found that COPD was associated with a greater risk of venous thromboembolism (VTE).⁹ These findings were confirmed later in a cohort study, which found that COPD patients had a 1.6-fold higher risk of VTE compared to the general population. Additionally, VTE was a strong predictor of all-cause mortality, especially in patients with severe COPD.¹⁰ In summary, patients with AE-COPD have an increased risk of VTE, but the possible beneficial effect of anticoagulant (AC) therapy to patients with COPD is unresolved. Therefore, the study aimed to evaluate whether pre-existing AC therapy may reduce the risk of hospitalization due to AE-COPD and death by all causes in COPD patients.

Methods

Study design

This is a national cohort study of COPD outpatients in Denmark.

Data sources

We used data from nationwide administrative registers. The following registers were used:

The Danish Register of Chronic Obstructive Pulmonary Disease (DrCOPD) contains individual and quality-assured data on age, gender, Forced Expiratory Volume after 1 s (FEV₁), Body Mass Index (BMI), Medical Research Council Dyspnoea Scale (MRC), smoking status, hospitalization due to AE-COPD during the past year, prescriptions on inhaled corticosteroids, and all out-patient visits and hospital admissions due to AE-COPD since 1^st January 2010.

The Danish National Patient Register contains information on all Danish in-hospital and out-patient clinic contacts since 1977. We assessed data on patients’ comorbidities within 10 years prior to study entry: heart failure, ischaemic heart disease, atrial fibrillation, pulmonary embolism, deep venous thrombosis, hypertension, diabetes mellitus type 1, diabetes mellitus type 2, renal failure, asthma, cerebrovascular disease, and malignant disease. Furthermore, data on hospitalization due to AE-COPD within one year after study entry was obtained from the register. Definitions of the diagnoses are presented in Table 1.

The Danish National Database of Reimbursed Prescriptions was used to assess data on AC therapy, acetylsalicylate, and beta-blocker treatment (ATC-codes in Table 2) during one year prior to study entry. This register contains information on all reimbursed drugs sold in community pharmacies and hospital-based outpatient pharmacies in Denmark since 2004. AC therapy was defined as at least one prescription during the one year prior to study entry. According to current Danish guidelines, patients with the following conditions indicate AC therapy: mechanical heart valve, moderate to severe mitral stenosis, severe renal failure, antiphospholipid syndrome, atrial fibrillation or flutter, venous thromboembolism, or intracavitary thrombosis.¹¹ Betablocker treatment was defined as at least two prescriptions during the one year prior to study entry.

The Cause of Death register contains data on the cause, date, location of death, and post-mortem data on Danes since 1970. We assessed the date of death of the patients included in this study.

Table 1.

ICD10 classification of diseases.

Diseases	ICD10 Definition
Heart failure	I50
Ischaemic heart disease	I21-I22, I25
Atrial fibrillation	I48
Pulmonary embolism	I26
Deep venous thrombosis	I801-I803, I808, I809, I821-I823, I828, I829
Hypertension	I10-I15
Peripheral vascular disease	I70.I74, I77, I79
Renal failure	I120, I131, I132, E102, E112, E122, E132, E142, N02-N08, N11, N14, N150, N158, N168, N162-N164, N169, N18, N19, N26, Z992
Cerebrovascular disease	I60-I64, G458, G459
Dementia	F00-F03, G30
Diabetes Mellitus, type 1	E10
Diabetes Mellitus, type 2	E11
Asthma	J45
Peptic ulcer	K25-K28
Rheumatologic diseases
Rheumatoid arthritis	M05-M06
Systemic Lupus erythematosus	M32
Dermatomyositis	M33
Systemic scleroderma	M34
Sjogren syndrome, polymyalgia rheumatica, and other generalized rheumatic diseases	M35-M36
Hemiplegia	G80-G83
Liver failure
Mild	B18, K73-K74, K700-K703, K709, K713-K715, K717, K760, K762-K764, K768-K769
Severe	I850, I859, I864, I982, K704, K711, K721, K729, K765-K767
Malignant disease localized to
Oropharyngeal organs	C00-C14
Gastrointestinal organs	C15-C26
Respiratory and intrathoracic organs	C30-C39
Bones and articular cartilage	C40-C41
Malignant melanoma	C43
Mesothelial and soft tissue	C45-C49
Breast	C50
Female genital organs	C51-C58
Male genital organs	C60-C63
Urinary tract	C64-C68
Central nervous system (incl. eye and brain)	C69-C72
Endocrine gland	C73-C75
Unspecified	C76-C80
Lymphoid or haematopoetic	C81-C96
Multiple sites	C97

Table 2.

ATC codes.

Anticoagulant Therapy	Name	ATC code
Non-vitamin K antagonist oral anticoagulants	Eliquis	B01AF02
	Lixiana	B01AF03
	Pradaxa	B01AE07
	Xarelto	B01AF01
Vitamin K antagonists	Marcoumar	B01AA04
Vitamin K antagonists	Warfarin	B01AA03
Other medications
Acetylsalic acid		B01AC06
Beta-blocker	Metoprolol	C07AB02

Population

We included all patients with COPD above 40 years of age, who were registered with an out-patient-clinic visit from the 1^st January 2010 to 31^st December 2018 in DrCOPD. Study entry was defined as the date of the first out-patient-clinic visit in DrCOPD. Patient baseline characteristics were assessed at study entry. Due to a strong association between malignant neoplasm, mortality, and hospitalizations, we excluded all patients with malignant neoplasms (except other skin cancers than malignant melanoma) (Table 1) within five years before study entry. Patients diagnosed with malignant neoplasms more than five years before study entry remained in the study cohort since we expected their mortality and hospitalizations rates to be similar to the background population. The flowchart of inclusion is presented in Figure 1.

Figure 1.

Flowchart of inclusion of the study cohort.

Outcome measures

The primary outcome was a combined endpoint of hospitalization due to AE-COPD or all-cause mortality. Secondary outcomes were all-cause mortality, AE-COPD admission, and the number of PE and DVT. All endpoints were evaluated after one year from baseline. Patients were censored at the first event.

Ethics

Danish Data Protection Agency approved this study (journal no. VD-2018-264, with I-Suite no. 6504). Informed consent and ethical approval from the patients are not required for registry-based studies according to current Danish legislation. The data from the different registries have been compiled by using encrypted unique personal identification numbers.¹²

Statistical methods

In case of missing BMI, FEV₁, or MRC at any visit, the last observation was carried forward. If values were missing from all visits, the patients received the median value.

A subpopulation was formed using a greedy-match propensity score.¹³ Patients in pre-existing AC therapy were matched in a 1:1 ratio with patients without AC therapy. The patients were matched on characteristics at study entry; age, gender (male/female), BMI, smoking status (current/not-current smokers), FEV₁, inhaled corticosteroids (yes/no), previous DVT (yes/no), previous PE (yes/no), heart failure (yes/no), ischemic heart disease (yes/no) and Metoprolol prescription (yes/no). AC therapy for patients with atrial fibrillation is decided upon the CHA2DC2-VASc score, which is based on the patient's characteristics such as age, gender, and cardiovascular comorbidities.¹⁴ Thus we were not able to match the population completely since patients with atrial fibrillation on AC therapy are not comparable to patients with atrial fibrillation without AC therapy. Additionally, we calculated a modified Charlson Comorbidity Index (CCI) score based on patients’ comorbidities; Apoplexia cerebri, dementia, peptic ulcer, diabetes mellitus, renal failure, liver failure (mild or severe), peripheral vascular disease, hemiplegia, and connective tissue diseases. Regarding AIDS/HIV, which typically are included in the CCI, we decided not to include the diagnoses because they are not considered to decrease life expectancy if treated.

The primary endpoint was evaluated in a univariable analysis on the propensity-score matched subpopulation. We tested whether there is an interaction between AC therapy and 1) smoking, 2) atrial fibrillation, or 3) congestive heart failure towards the primary outcome. We report no interaction between AC therapy and smoking, nor between AC therapy and atrial fibrillation. We found a positive interaction in the heart failure interaction analysis, p = 0.03. Therefore the primary analysis was stratified for congestive heart failure. Furthermore, a sensitivity analysis was performed to evaluate the endpoint in a multivariable analysis, including the whole cohort. A competing risk model was performed to evaluate the secondary endpoint of death and AE-COPD after 1 year. The number of DVT and PE was evaluated by Fischer's Exact Test

Cox proportional hazard regression models are presented as hazard ratios (HRs) with 95% CI. Statistical analyses were performed using SAS statistical software 9.4. Plots were customized by the NewSurv macro.¹⁵

Results

Between 1^st January 2010 and 31^st December 2018, 58,067 individual COPD outpatients were identified in DrCOPD, of these 43 patients emigrated within the first year from baseline and therefore only followed until the date of emigration. In the cohort, we identified 5194 patients who claimed at least one prescription for AC therapy one year prior to study entry. The majority of the patients’ (79.5%) first anticoagulant prescription was vitamin-K-antagonist, and fewer patients (20.5%) claimed non-vitamin K antagonist oral anticoagulants as their first AC therapy prescription. The baseline characteristics of the study population are presented in Table 3. The groups differed in every variable except malignant diagnoses and treatment with inhalation medication prior to matching. After propensity-scores matching the two groups were fairly comparable except for the number of patients with atrial fibrillation (70.7% on AC therapy vs. 29.3% not receiving AC therapy). The propensity-score matched population included a total of 10,360 outpatients, and the patient characteristics are presented in Table 4.

Table 3.

Baseline characteristics of the total study population.

	All patients	Patients without AC therapy	Patients with AC therapy
Number of patients, n (%)	58067 (100)	52873 (91.1)	5194 (8.9)
Age, median (IQR)	70.0 (62.1, 77.3)	69.5 (61.5, 76.8)	75.4 (68.8, 80.9)
Gender female, n (%)	30437 (52.4)	28201 (53.3)	2236 (43.0)
FEV1, % (IQR)	49 (37, 62)	49 (37, 62)	49 (39, 62)
MRC, median (IQR)	3 (2, 4)	3 (2, 4)	3 (2, 4)
BMI, median (IQR)	25 (22, 29)	25 (22, 28)	25 (23, 30)
AE-COPD within past year, n (%)	12616 (21.7)	11339 (21.5)	1277 (24.6)
Current smokers, n (%)	19275 (33.2)	18088 (34.2)	1187 (22.9)
Medication
ICS, n (%)	39647 (68.3)	36164 (68.4)	3483 (67.1)
ICS + LABA/LAMA, n (%)	38043 (65.5)	34690 (65.6)	3353 (64.6)
LABA/LAMA, n (%)	46486 (80.1)	42280 (80.0)	4205 (81.0)
ASA, n (%)	22535 (38.8)	20434 (28.7)	2101 (40.5)
Metoprolol, n (%)	7663 (13.2)	5700 (10.8)	1963 (37.8)
Comorbidities
Heart failure, n (%)	7717 (13.3)	5922 (11.2)	1795 (34.6)
Ischaemic heart disease, n (%)	9794 (16.9)	8352 (15.8)	1442 (27.8)
Atrial fibrillation, n (%)	13888 (23.9)	9736 (18.4)	4152 (79.9)
Pulmonary embolism, n (%)	3351 (5.8)	2390 (4.5)	961 (18.5)
Deep venous trombosis, n (%)	1932 (3.33)	1342 (2.5)	590 (11.4)
Hypertension, n (%)	24885 (42.9)	21786 (41.2)	3099 (59.7)
Diabetes Mellitus 1, n (%)	2037 (3.5)	1769 (3.4)	268 (5.2)
Diabetes Mellitus 2, n (%)	6087 (10.5)	5234 (9.9)	853 (16.4)
Renal failure, n (%)	5351 (9.2)	4457 (8.4)	894 (17.2)
Asthma, n (%)	12656 (21.8)	11658 (22.1)	998 (19.2)
Cerebrovascular disease, n (%)	9225 (15.9)	8050 (15.2)	1175 (22.6)
Malignant disease more than five years prior to study entry, n (%)	9253 (15.9)	8378 (15.9)	875 (16.9)
Charlson comorbidity index^m
0, n (%)	28759 (49.5)	26877 (50.8)	1882 (36.2)
1, n (%)	11674 (20.1)	10457 (19.8)	1217 (23.4)
≥2, n (%)	17634 (30.4)	15539 (29.4)	2095 (40.3)

Patient characteristics assessed at study entry. Comorbidities are within 10 years prior to baseline, except for malignant diseases which are >5 years prior because patients with malignant diseases within 5 years prior to baseline were excluded.

Abbreviations: Forced Expiratory Volume after 1 s (FEV1), Body Mass Index (BMI), Medical Research Council Dyspnoea Scale (MRC), Acute Exacerbation of COPD (AE-COPD), Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA), Anticoagulant therapy (AC therapy).

Modified index score: based on the following comorbidities: Apoplexia cerebri, dementia, peptic ulcer, diabetes mellitus, renal failure, liver failure (mild or severe), peripheral vascular disease, hemiplegia, and connective tissue diseases.

Table 4.

Baseline characteristics of the propensity-score matched study population.

	Patients without AC treatment[Controls]	Patients with AC treatment[Cases]
Number of patients, n (%)	5180 (50)	5180 (50)
Age, median (IQR)	75.8 (68.9, 81.7)	75.4 (68.8, 80.9)
Gender female, n (%)	2185 (42.2)	2229 (43.0)
FEV1, % (IQR)	49 (40, 62)	49 (39, 62)
MRC, median (IQR)	3 (2, 4)	3 (2, 4)
BMI, median (IQR 25)	26 (23, 30)	25 (23, 30)
AE-COPD within past year, n (%)	1041 (20.1)	1274 (24.6)
Current smokers, n (%)	1163 (22.5)	1186 (22.9)
Medication
ICS, n (%)	3500 (67.6)	3473 (67.1)
ICS + LABA/LAMA, n (%)	3382 (65.3)	3345 (64.6)
LABA/LAMA, n (%)	4214 (81.4)	4196 (81.0)
ASA, n (%)	2897 (55.9)	2095 (40.4)
Metoprolol, n (%)	1937 (37.4)	1951 (37.7)
Comorbidities
Heart failure, n (%)	1824 (35.2)	1782 (34.4)
Ischaemic heart disease, n(%)	1532 (29.6)	1437 (27.7)
Atrial fibrillation, n (%)	1714 (33.1)	4138 (79.9)
Pulmonary embolism, n (%)	888 (17.1)	948 (18.3)
Deep venous trombosis, n (%)	531 (10.3)	583 (11.3)
Hypertension, n (%)	2953 (57.0)	3089 (59.6)
Diabetes Mellitus 1, n (%)	304 (5.9)	268 (5.2)
Diabetes Mellitus 2, n (%)	859 (16,6)	853 (16,5)
Renal failure, n (%)	834 (16,1)	892 (17,2)
Astma, n (%)	972 (18,8)	995 (19,2)
Cerebrovascular disease, n (%)	1028 (19,9)	1170 (22,6)
Malignant disease more than five years prior to study entry, n (%)	871 (16,8)	869 (16.8)
Charlson comorbidity index^m
0, n (%)	2012 (38.8)	1878 (36.3)
1, n (%)	1121 (21.6)	1215 (23.5)
≥2, n (%)	2047 (39.5)	2087 (40.3)

Modified index score: based on the following comorbidities: apoplexy, dementia, peptic ulcer, diabetes mellitus, renal failure, liver failure (mild or severe), peripheral vascular disease, hemiplegia, and connective tissue diseases.

Outcomes

The number of deaths and AE-COPD hospitalizations in the total cohort and the propensity-matched population after one year of follow-up is presented in Table 5.

Table 5.

Mortality and AE-COPD hospitalization in the study cohort.

	Death within 365 days	p-value	AE-COPD within 365 days	p-value
Total population, n (%)	6333 (10.9)		10373 (17.9)
Patients with AC therapy, n (%)	893 (17.2)	<0.0001	1186 (22.8)	<0.0001
Patients without AC therapy, n (%)	5440 (10.3)		9187 (17.4)
Propensity matched population	1729 (16.7)		2283 (22.0)
Patients in AC therapy, n (%)	888 (17.1)	0.2255	1181 (22.8)	0.0645
Patients without AC therapy, n (%)	841 (16.2)		1102 (21.3)

Abbreviations: Anticoagulant (AC), Acute Exacerbations of COPD (AE-COPD).

We found no association between the risk of AE-COPD hospitalization or all-cause mortality and AC therapy in the propensity-score matched population in the primary analysis, which was adjusted for CCI score [modified] (HR 1.03, 95% CI 0.96-1.10, p = 0.3555) Figure 2. When stratifying for congestive heart failure, the risk was also unaltered for patients with heart failure on AC therapy (HR 0.90, 95% CI 0.81-1.00, p = 0.0514). For patients without congestive heart failure on AC therapy, we found an increased risk of AE-COPD or all-cause mortality after 365 days (HR 1.15, 95% CI 1.05-1.26, p = 0.0023).

A competing risk analysis of the propensity-score matched population applying all-cause mortality as a competing risk to AE-COPD hospitalization showed no difference in risk of AE-COPD between the two groups (HR 0.96, 95% CI 0.87–1.05, p = 0.3520), and also no difference in mortality after 365 days (HR 1.02, 95% CI 0.91–1.16, p = 0.70).

In the propensity-matched population, the number of patients registered with PE within 365 days in the group without AC therapy was 147 patients (2,8%) and 105 patients (2.0%) in the group with AC therapy (p = 0.01). The number of patients registered with DVT within 365 days in the group without AC therapy was 65 patients (1.3%) and 60 patients (1.2%) in the group with AC therapy (p = 0.72). Regarding simultaneous PE and DVT, 12 patients without AC therapy and 6 patients with AC therapy were registered with both diagnoses simultaneously.

Figure 2.

Time (days) to hospitalization due to AE-COPD or all-cause mortality in patients with or without AC therapy in the propensity-score matched population.

Sensitivity analyses

Multivariable analysis of the total population of 58,067 patients adjusted for age, gender, smoking status, FEV₁, BMI, use of inhaled corticosteroids, heart failure, ischaemic heart disease, DVT, and PE showed an increased risk of hospitalization due to AE-COPD or all-cause mortality within 365 days in the group of patients receiving AC therapy compared to the patients without AC therapy (HR 1.10, 95% CI 1.04–1.16, p = 0.0005).

Discussion

This is the first study to investigate if pre-existing AC therapy could be related to improved prognosis in a large cohort of patients with COPD. We found, that AC therapy in this population of severe COPD outpatients did not reduce the risk of hospitalization due to AE-COPD or all-cause mortality within 365 days in the primary analysis of the propensity-score matched subpopulation. A secondary analysis was performed to estimate the separate outcomes of hospitalization due to AE-COPD after one year using a competing risk model, in which all-cause mortality was accounted for as a competing risk. The signal remained unchanged. In the sensitivity analysis, an adjusted analysis of the total cohort, we found a slightly increased risk of hospitalization due to AE-COPD or all-cause mortality in patients with AC therapy. Stratified for congestive heart failure, the risk associated with AC therapy for all-cause mortality or AE-COPD was unaltered for patients with heart failure but slightly increased for patients without heart failure. Further, we found no difference in the frequency of venous thromboembolisms within one year from baseline.

In a small study of patients with atrial fibrillation, a subgroup analysis of patients with concomitant COPD indicated that treatment with oral AC was associated with a decreased risk of death.¹⁶ Explanations for the discrepancy between these results and the present study results include reverse bias by indication (patients with atrial fibrillation not receiving AC therapy, will most often not be following guidelines) and type I error in the other study, and further that we chose not to stratify for atrial fibrillation to avoid reverse bias by indication. Atrial fibrillation is very common among patients with COPD, and in our study, we found a higher prevalence than described in the literature¹⁷ or the same,¹⁸ which is not unreasonable when considering the severity of COPD in our population. Atrial fibrillation is an independent predictor of death in patients with COPD.^19–22 Thus, our neutral results may be explained by a “neutralizing effect” i.e. benefits from AC therapy and attributable risk to atrial fibrillation, since nearly all patients in AC therapy had atrial fibrillation.

Among patients with heart failure, we did not observe any association between AC therapy and AE-COPD or all-cause mortality. These findings are consistent with earlier studies evaluating the effect of AC therapy on mortality in patients with heart failure.^23,24 The small increased risk of AE-COPD or all-cause mortality among patients without heart failure in the present study could probably be due to underlying factors.

VTE during COPD exacerbation is considered to be associated with a worse prognosis.²⁵ Unfortunately, both stable COPD and AE-COPD are associated with a hypercoagulable state.^26,27 Mechanisms to explain the association between COPD and change in coagulability primarily include systemic chronic inflammation (increases of C-reactive protein, fibrinogen, interleukins 6 and 8, and tumor necrosis factor α), and secondarily hypoxia-related platelet activation and oxidative stress.²⁸ Circulating active coagulation factors (e.g. Factor XI and tissue factor) have also been found in patients with COPD.²⁹ In our study, VTE was very infrequently present as an event in the national health register, and the frequency of DVT³⁰ and PE^7,31–34 in our study is much lower than other findings, which indicates that the register may not be sensitive to this outcome. Perhaps due to a clinical underdiagnosing, since PE can occur in COPD patients with acute respiratory symptoms even without clinical suspicion.⁷

This nationwide study had a large sample size since DrCOPD contains data on all COPD outpatient visits between 1^st January 2010 and 31^st December 2018, therefore chance findings are unlikely. We partly overcame information bias by using the Danish national registers to obtain data on patient characteristics (e.g. age, FEV₁, smoking, and BMI), comorbidities, and outcomes. The registers are known to have a high degree of completeness and are regularly validated, and thus lead-time bias is unlikely. Second, we had a complete follow-up, since all admissions and deaths are entered into the Danish national registers in real-time. Despite these strengths, some limitations deserve careful consideration: There may be some compliance bias, thus we defined AC therapy as at least one prescription during the one year prior to study entry, but we are not able to know if the patients adhered to the therapy. Therefore we might underestimate the possible beneficial effect of AC therapy. Furthermore, there may be some diagnostic bias as the control and case group are not completely identical. Lastly, due to the observational study design, it is impossible to account for unknown confounders fully.

In conclusion, AC therapy did not appear to be beneficial or, in a clinically meaningful way, harmful to patients with severe COPD. However, even with the large sample size and complete follow-up, the registered incidence of VTE was low and all events may not have been registered. Our findings need confirmation in other settings and other geographical regions.

Contribution

AK, JE, and JSJ contributed to the conception and design of the study, data collection and analysis, data interpretation, and writing the manuscript. PS, RS, and TSI contributed to the conception and design of the study, data interpretation, and revising the manuscript. KB contributed to the data collection and revising the manuscript. All authors have approved the final manuscript and agreed to be accountable for all aspects of the work.

Footnotes

Acknowledgments

We thank Barbara Bonnesen Bertelsen, MD, cand.scient.biol for graphical support.

Data availability

Data are not publicly available but can be obtained through appropriate approval. According to Danish legislation regarding sharing of population data, source data collected for this study cannot be made available for others. However, Danish citizens who have a legitimate reason can apply for access to the data via the Danish National Health Authority.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

A Kristensen

K Bagge

Author biographies

A Kristensen is a Medical Student at Copenhagen University. She will finish her degree in 2023. During her medical studies, she has been very interested in internal medicine, and her research focuses on the interaction between the pulmonary and cardiovascular systems.

P Sivapalan is a Postdocs at Department of Internal Medicine, Section of Respiratory Medicine, Herlev and Gentofte University Hospital. He received his PhD in 2019. His current research focuses on personalized treatment for patients with Chronic Obstructive Pulmonary Disease.

K Bagge is a medical doctor at Department of Clinical Microbiology, Amager and Hvidovre University Hospital. His current research focuses on antibiotic treatment to patient with pulmonary disease.

T Biering-Sørensen is a Professor at the Department of Biomedical Sciences, University of Copenhagen and the Director of Cardiac Imaging at Department of Internal Medicine, Section of Respiratory Medicine, Herlev and Gentofte University Hospital. He received his PhD in 2015 from the University of Copenhagen. His current research focuses on optimizing the cardiovascular imaging in clinical practice.

R Sørensen is a medical doctor and consultant in Interventional Cardiology, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet. She received her PhD in 2011. Her current research focuses on anticoagulant therapy to patients with acute myocardial infarction.

J Eklöf is a Postdocs at Department of Internal Medicine, Section of Respiratory Medicine, Herlev and Gentofte University Hospital. She received his PhD in 2020. Her current research focuses on recurrent Pseudomonas aeruginosa infection in patients with Chronic Obstructive Pulmonary Disease.

JUS Jensen is a Professor of Respiratory Medicine in Department of Clinical Medicine, University of Copenhagen and Head of research at Department of Internal Medicine, Section of Respiratory Medicine, Herlev and Gentofte University Hospital. He received his PhD in 2011. He is specialized in sepsis, respiratory failure and biomarker research.

References

Murray

CJL

Lopez

. Measuring the global burden of disease. N Engl J Med 2013; 369: 448–457.

Kim

Aaron

. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J 2018; 52: 1801261.

Ritchie

Wedzicha

. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med 2020; 41: 421–438.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - 2019 report. Glob Initiat Chronic Obstr Lung Dis Inc. 2019.

Johannesdottir

Christiansen

Johansen

, et al. Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based danish cohort study. J Med Econ 2013; 16: 897–906.

Aleva

Voets

LWLM

Simons

, et al. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: a systematic review and meta-analysis. Chest 2017; 151: 544–554.

Couturaud

Bertoletti

Pastre

, et al. Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms. JAMA 2021; 325: 59–68.

Maclay

McAllister

Johnston

, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011; 66: 769–774.

Kubota

London

Cushman

, et al. Lung function, respiratory symptoms and venous thromboembolism risk: the atherosclerosis risk in communities study. J Thromb Haemost 2016; 14: 2394–2401.

10.

Børvik

Brækkan

Enga

, et al. COPD And risk of venous thromboembolism and mortality in a general population. Eur Respir J 2016; 47: 473–481.

11.

The Danish Society of Cardiology, Anticoagulant therapy [Internet]. Vol. 42. [cited 2022 Feb 21]. Available from: https://nbv.cardio.dk/ak

12.

Thygesen

Daasnes

Thaulow

, et al. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health 2011; 39: 12–16.

13.

D’Agostino

. Propensity scores in cardiovascular research. Circulation 2007; 115: 2340–2343.

14.

The Danish Society of Cardiology, Atrial fibrillation and flutter [Internet]. [cited 2022 Feb 21]. Available from: ht tps://nbv.cardio.dk/af

15.

Meyers

. https://communities.sas.com/t5/SAS-Communities-Library/Kaplan-Meier-Survival-Plotting-Macro-NEWSURV/ta-p/479747.

16.

Rodríguez-Mañero

López-Pardo

Cordero

, et al. A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population. Int J Chronic Obstr Pulm Dis 2019; 14: 371–380.

17.

Mapel

Dedrick

Davis

. Trends and cardiovascular co-morbidities of COPD patients in the veterans administration medical system, 1991–1999. COPD 2005; 2: 35–41.

18.

Konecny

Park

Somers

, et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 2014; 114: 272–277.

19.

Abdullah

Eigbire

Ali

, et al. Relationship of atrial fibrillation to outcomes in patients hospitalized for chronic obstructive pulmonary disease exacerbation. J Atr Fibrillation 2019; 12: 2117.

20.

Xiao

Han

, et al. Prevalence of atrial fibrillation in hospital encounters with End-stage COPD on home oxygen: national trends in the United States. Chest 2019; 155: 918–927.

21.

Desai

Patel

Singh

, et al. The burden and impact of arrhythmia in chronic obstructive pulmonary disease: insights from the national inpatient sample. Int J Cardiol 2019; 281: 49–55.

22.

Tomioka

Fukui

Tanaka

, et al. Influence of atrial fibrillation on cardiac prognosis in chronic obstructive pulmonary disease. Indian Heart J 2019; 71: 7–11.

23.

Sulaica

Macaulay

Helbing

, et al. A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis. Heart Fail Rev 2020; 25: 207–216.

24.

Beggs

SAS

Rørth

Gardner

, et al. Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart 2019; 105: 1325–1334.

25.

Cao

Dong

Cao

. Pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease. Chin Med J (Engl) 2018; 131: 1732–1737.

26.

Kyriakopoulos

Gogali

Kostikas

, et al. Hypercoagulable state in copd-a comprehensive literature review. Diagnostics (Basel) 2021; 11: 1447.

27.

Polosa

Malerba

Cacciola

, et al. Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients. Intern Emerg Med 2013; 8: 567–574.

28.

Keramidas

Gourgoulianis

Kotsiou

. Venous thromboembolic disease in chronic inflammatory lung diseases: knowns and unknowns. J Clin Med 2021; 10: 2061.

29.

Jankowski

Undas

Kaczmarek

, et al. Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation. Thromb Res 2011; 127: 242–246.

30.

Ambrosetti

Ageno

Spanevello

, et al. Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res 2003; 112: 203–207.

31.

Tillie-Leblond

Marquette

C-H

Perez

, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006; 144: 390–396.

32.

Akpinar

Hoşgün

Akpinar

, et al. Incidence of pulmonary embolism during COPD exacerbation. J Bras Pneumol 2014; 40: 38–45.

33.

Soriano

Abajobir

Abate

, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017; 5: 691–706.

34.

Rizkallah

Man

SFP

. Prevalence of pulmonary embolism in acute exacerbations of COPD. Chest 2009; 135: 786–793.